many analgesic products contain combinations of different drugs. There are few direct comparisons of these combinations, but several appear to be no more effective than an appropriate dose of one of their individual analgesic components. many combinations should be avoided because they contain drugs that have significant adverse effects or that do not contribute to the analgesic effect. Some combinations can be obtained without a prescription. Patients may inadvertently overdose themselves if they take several of these products simultaneously.
Introduction
There are at least 40 different combination analgesic preparations available in Australia. Most of these are combinations of paracetamol 500 mg with codeine in doses ranging from 8 mg to 30 mg. 1 A number of preparations also contain doxylamine, a sedating antihistamine with anticholinergic effects. 2 There are also other preparations available which contain paracetamol and dextropropoxyphene, aspirin and codeine, aspirin and dihydrocodeine, and ibuprofen and codeine. 1 Internationally, preparations containing paracetamol with other opioids such as oxycodone and tramadol are available.
Regulation
The Australian scheduling of combination analgesics under poisons regulations is determined by the dose of codeine per tablet, the number of tablets in a pack, and the other drugs in the combination (for example doxylamine). All preparations containing 30 mg codeine in combination with paracetamol or aspirin are Schedule 4. They therefore require a prescription.
Preparations with doses of codeine 15 mg or less have been available as Schedule 2 (pharmacy medicine) or 3 (pharmacistonly medicine), but from 1 May 2010 they were no longer available in Schedule 2. Combination analgesics containing up to 12 mg codeine are pharmacist-only, and those containing more than 12 mg are prescription-only. The pharmacist-only products are limited to no more than five days of treatment. 3 
evidence of efficacy
Paracetamol or a non-steroidal anti-inflammatory drug (NSAID) given with a strong opioid such as morphine in a multimodal analgesic regimen for acute pain, reduces the amount of opioid used, improves analgesia and reduces the duration of patientcontrolled analgesia. 4 However, data supporting products which combine a weak opioid, such as codeine, with paracetamol or an NSAID, are limited. There is much variability in the dose of weak opioid contained in combination products, and the role of codeine in managing acute pain is unclear. Analgesic guidelines state that 'although codeine is widely used, its place in therapy is uncertain'. 5 The National Prescribing Service (NPS) has stated that 'studies in acute pain suggest only modest additional analgesic efficacy when a weak opioid is added to paracetamol, but a higher rate of adverse effects after repeated doses'. 6 There is consensus that paracetamol is the first-line treatment for many acute pain states. [4] [5] [6] [7] [8] The Oxford Pain group has developed a league table of analgesic efficacy for most common oral analgesics. This uses data from systematic reviews of randomised, double-blind, single-dose studies of patients with moderate to severe pain where the outcome is a reduction of pain by at least 50% in 4-6 hours. Data are expressed as:
n the number of patients who need to be treated (NNT) for one to get 50% relief n the percentage of patients with at least 50% pain relief (Table 1 ).
There are limitations to these data. Often the trial sample size is small so there may be wide confidence intervals, they are not 
Paracetamol with codeine
A Cochrane review found that paracetamol with codeine is more effective in acute postoperative pain than paracetamol alone. The NNT to achieve 50% pain relief at 4-6 hours was 2. For dental pain, the most effective approach is to undertake appropriate dental treatment. After dental extraction the efficacy of NSAIDs is superior to that of combinations of paracetamol and codeine. 11, 12 The Therapeutic Guidelines: Oral and Dental recommend that if a combination is used, the dose of codeine should be at least 25 mg and suggest that a codeine dose of 60 mg with paracetamol 1 g will be required for severe dental pain. 11
Dextropropoxyphene
Overdoses of dextropropoxyphene can be fatal. There are concerns about accumulation of a toxic metabolite of dextropropoxyphene in patients with renal impairment. 5 The drug has been withdrawn in the UK and is being withdrawn in New Zealand.
Dextropropoxyphene is a weak opioid, but in combination with paracetamol it provides no increase in analgesia and has more adverse effects than paracetamol alone. 5 The Oxford league 
Doxylamine
There is no evidence that doxylamine has any analgesic efficacy, but this sedating antihistamine may be a component of compound analgesics. Doxylamine may be subject to abuse and combination analgesic preparations containing it cannot be recommended.
opioids in combination with NSAIDs
While there is a significant body of evidence identifying the efficacy of NSAIDs in acute pain, there are limited data on combining them with opioids. Many NSAIDs, in single-dose studies, show greater efficacy than codeine in combination with paracetamol or codeine in combination with aspirin. 9 Aspirin 650 mg in combination with codeine 60 mg is effective in postoperative pain with an NNT of 5.3 for at least 50% pain relief over 4-6 hours in patients with moderate to severe pain compared with placebo. This appears to be less effective than 
Chronic pain
The evidence for long-term efficacy of opioids in chronic pain is limited. Opioids should only be considered as a component of a multidimensional management plan. In general, opioids other than codeine should be chosen. One exception is osteoarthrosis of the hip, for which there is some evidence for efficacy of codeine. 5 Opioid analgesics should be avoided in headache because of the risk of dependence and medication overuse headache. 4, 8 Adverse effects and toxicity
Opioids and compound analgesics have a substantially increased risk of adverse effects compared with paracetamol alone. 7 These adverse effects include constipation, nausea, vomiting and drowsiness. The elderly appear to be more susceptible to adverse effects. 5 Abuse of, and dependence on, codeine-containing combination analgesics is a poorly quantified, but likely significant, risk. 14 Codeine is converted to morphine by cytochrome P450 2D6, but 7-10% of the Caucasian population lack this enzyme. These 'poor metabolisers' of codeine will get no analgesic benefit, but may experience adverse effects. 5 A significant proportion of cases of acute liver failure are from unintentional paracetamol overdose. Many of these patients have taken more than one paracetamol-containing preparation simultaneously. 15 Indirect comparisons show that the combination of aspirin and codeine may be less efficacious than aspirin alone and therefore the combination cannot be recommended. Given the lack of documented analgesic efficacy of low-dose codeine preparations, rescheduling of codeine in Australia is unlikely to impact significantly on analgesic options, but may reduce the harms from overuse.
Conclusion

